DelveInsight’s “Chronic Rhinosinusitis with Nasal Polyps PipelineInsight 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Rhinosinusitis with Nasal Polyps pipeline landscape.
In the ANCHOR-1 and ANCHOR-2 trials, depemokimab demonstrated significant reductions in nasal polyp size and nasal obstruction versus placebo in patients with chronic rhinosinusitis with nasal ...
Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose.
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function... .
Beekeeper’s Naturals has issued a voluntary nationwide recall of its saline nasal spray due to possible microbial contamination ... RELATED STORY . Bayer recalls Afrin travel-size nasal spray over labeling error.
Polyrizon Advances NASARIX™ Development with Key HumanStudy to Characterize Nasal Residence Time and SupportFDA Regulatory Pathway... The study is designed to evaluate the nasal residence time of the ...
The nasal spray, Beekeeper’s Naturals SalineNasalSpray, was sold through the online retailer and "tested above our acceptable microbiological limits for yeast," Beekeeper’s Naturals stated in the announcement on the FDA's website.
GHRP-6NasalSpray affects GH receptor binding by acting as a full agonist at the growth hormone secretagogue receptor ... That historical detail matters for understanding what GHRP-6 Nasal Spray actually does at the receptor level.